Complete Clinical Cure | ||||||
Study | Patients | Comparison | Follow up | RR | 95% CI | p value |
Balagon, 2010 [18] | PB | MDT vs. 28 days of RFP + ofloxocin for 4w then 5 months of placebo | 6 m | 4.2 | 2.25–7.85 | < 0.05 |
12 m | 0.93 | 0.80–1.09 | 0.38 | |||
Bathe, 1986 [19] | MDT vs. MDT+ clofazimine in alternative days for 6 m | 6 m | 1.25 | 0.77–2.04 | 0.37 | |
24 m | 1.09 | 0.93–1.27 | 0.29 | |||
Orege, 1990 [26] | MDT vs. Modified MDT (MDT + RFP + dapsone)a | 6 m | 0.76 | 0.61–0.95 | 0.02 | |
Clinical Improvement | ||||||
Study | Patients | Comparison | Follow up | MDT | Control | |
Rao, 2009 [27] | PB | MDT vs RFP + dapsone + clofazimine (good) | 24 m | 6/11 (52%) | 7/9 (78%) | |
MDT vs RFP + dapsone + clofazimine (moderate) | 3/11 (27%) | 2/9 (22%) | ||||
MB | MDT vs RFP + dapsone + clofazimine (good) | 13/17 (77%) | 1/4 (25%) | |||
MDT vs RFP + dapsone + clofazimine (moderate) | 3/17 (17%) | None | ||||
Sampoonachut, 1997 [36] | MDT vs. MDT + ofloxacin. | 36 m | 66.70% | 73.30% | ||
MDT vs. ofloxacin + clofazimine, then MDT | 66.70% | 76.50% | ||||
Tejasvi, 2006 [39] | MDT vs. RFP + Sparfloxacin + clarithromycin + minocycline | 12 m | 66.66% | 73.92% | ||
Villahermosa, 2004 [40]b | MDT vs. ROM | 96 m | 22 points | 20 points | ||
Relapse | ||||||
Study | Patients | Comparison | Follow up | RR | 95% CI | p value |
Balagon, 2010 [18] | PB | MDT vs. 28 days of RFP + ofloxacin for 4w then 5 m of placebo | 12 m | 1.76 | 0.16–18.88 | 0.64 |
Katoch, 1999 [22] | MDT vs. MDT+ clofazimine | 24 m | 5 | 0.24–103.28 | 0.3 | |
Kumar, 2015 [23] | MDT vs. ROM | 24 m | 0.5 | 0.05–5.45 | 0.57 | |
96 m | 1.7 | 0.94–3.07 | 0.08 | |||
Manickam, 2012 [24] | MDT vs. ROM | 6 m | 1.43 | 0.56–3.64 | 0.46 | |
Fajardo 2009 [30] | MB | MDT 2y vs. MDT 1y + 1 month daily RFP/ofloxacin | 144 m | 0.51 | 0.05–5.46 | 0.58 |
MDT 2y vs. 1 month daily RFP/ofloxacin | 0.11 | 0.02–0.87 | 0.04 | |||
MDT 2y vs. MDT 1 y | 0.05 | 0.01–0.37 | < 0.05 | |||
Olivera Penna, 2017 [35] | MDT vs. RFP+ dapsone + clofazimine × 6 m | 60 m | 0.16 | 0.02–1.29 | 0.08 | |
Souza Cunha, 2012 [38] | MDT 1y vs. MDT x 2y | 84 m | 2.59 | 0.13–52.17 | 0.53 | |
MDT 1y vs. MDT + ofloxacin | 1.04 | 0.15–7.10 | 0.97 | |||
MDT 1y vs. ofloxacin + RFP | 0.13 | 0.03–0.51 | < 0.05 | |||
Villahermosa, 2004 [40] | MDT vs. ROM | 96 m | No events reported | |||
BI | ||||||
Study | Patients | Comparison | Follow up | MD | 95% CI | p value |
Bathki, 1992 [29] | MB | MDT vs. MDT + vaccine | 24 m | 1.3 | 0.48, 2.12 | < 0.05 |
Gunawan 2018 [32] | MDT vs. CDC | 3 m | 0.03 | −0.03,0.09 | 0.75 | |
Jadav, 1992 [33] | MDT vs. RFP + dapsone + clofazimine | 24 m | 0.41 | 0.12, 0.70 | < 0.05 | |
Olivera Penna, 2017 [35] | MDT vs. RFP+ dapsone + clofazimine × 6 m | 60 m | − 0.15 | −1.06,0.76 | 0.34 | |
Sampoonachut, 1997c [36] | MDT vs. MDT + ofloxacin. | 36 m | −0.07 | − 0.48, 0.34 | 0.74 | |
MDT vs. Ofloxacin + clofazimine, then MDT | −0.68 | −1.10, − 0.26 | < 0.05 | |||
Shaw, 2003c [37] | MDT vs. RFP + clofazimine+ acedapsone + dapsone | 24 m | 0.1 | − 0.34, 0.54 | 0.66 |